This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Jesper Lau, Ph.D.
Vice President, Chemical Biology at Novo Nordisk A/S

Agenda Sessions

  • KEYNOTE PRESENTATION: Discovery and Development of Semaglutide – The First Orally Available GLP-1 Peptide for Treatment of Type 2 Diabetes

    10:30am
  • LIVE Keynote Q&A Including Audience Interaction: Attendees Please Bring Your Questions to This Session

    11:00am
  • SESSION NAME: Cutting-Edge Technologies for Peptide Discovery - SESSION CHAIR & SPEAKERS BELOW

    On Demand